Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Chembiochem ; 13(14): 2082-93, 2012 Sep 24.
Artigo em Inglês | MEDLINE | ID: mdl-22907802

RESUMO

The serine hydrolases constitute a large class of enzymes that play important roles in physiology. There is great interest in the development of potent and selective pharmacological inhibitors of these proteins. Traditional active-site inhibitors often have limited selectivity within this superfamily and are tedious and expensive to discover. Using the serine hydrolase RBBP9 as a model target, we designed a rapid and relatively inexpensive route to highly selective peptoid-based inhibitors that can be activated by visible light. This technology provides rapid access to photo-activated tool compounds capable of selectively blocking the function of particular serine hydrolases.


Assuntos
Proteínas de Ciclo Celular/antagonistas & inibidores , Inibidores Enzimáticos/química , Peptídeos e Proteínas de Sinalização Intracelular/antagonistas & inibidores , Luz , Proteínas de Neoplasias/antagonistas & inibidores , Domínio Catalítico , Proteínas de Ciclo Celular/metabolismo , Inibidores Enzimáticos/metabolismo , Amarelo de Eosina-(YS)/química , Fluoresceína/química , Células HeLa , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Magnetismo , Proteínas de Neoplasias/metabolismo , Peptoides/síntese química , Peptoides/química , Ligação Proteica , Proteoma/metabolismo , Rutênio/química
2.
J Neurosci ; 29(24): 7820-32, 2009 Jun 17.
Artigo em Inglês | MEDLINE | ID: mdl-19535594

RESUMO

Although it is a widely studied psychiatric syndrome, major depressive disorder remains a poorly understood illness, especially with regard to the disconnect between treatment initiation and the delayed onset of clinical improvement. We have recently validated chronic social defeat stress in mice as a model in which a depression-like phenotype is reversed by chronic, but not acute, antidepressant administration. Here, we use chromatin immunoprecipitation (ChIP)-chip assays--ChIP followed by genome wide promoter array analyses--to study the effects of chronic defeat stress on chromatin regulation in the mouse nucleus accumbens (NAc), a key brain reward region implicated in depression. Our results demonstrate that chronic defeat stress causes widespread and long-lasting changes in gene regulation, including alterations in repressive histone methylation and in phospho-CREB (cAMP response element-binding protein) binding, in the NAc. We then show similarities and differences in this regulation to that observed in another mouse model of depression, prolonged adult social isolation. In the social defeat model, we observed further that many of the stress-induced changes in gene expression are reversed by chronic imipramine treatment, and that resilient mice-those resistant to the deleterious effects of defeat stress-show patterns of chromatin regulation in the NAc that overlap dramatically with those seen with imipramine treatment. These findings provide new insight into the molecular basis of depression-like symptoms and the mechanisms by which antidepressants exert their delayed clinical efficacy. They also raise the novel idea that certain individuals resistant to stress may naturally mount antidepressant-like adaptations in response to chronic stress.


Assuntos
Antidepressivos Tricíclicos/uso terapêutico , Cromatina/efeitos dos fármacos , Depressão/tratamento farmacológico , Depressão/patologia , Imipramina/uso terapêutico , Núcleo Accumbens/ultraestrutura , Animais , Comportamento Animal , Proteína de Ligação a CREB/metabolismo , Imunoprecipitação da Cromatina/métodos , Modelos Animais de Doenças , Dominação-Subordinação , Expressão Gênica/efeitos dos fármacos , Expressão Gênica/fisiologia , Estudo de Associação Genômica Ampla/métodos , Histonas/metabolismo , Masculino , Metilação/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL , Núcleo Accumbens/efeitos dos fármacos , Isolamento Social
3.
BMC Cancer ; 10: 397, 2010 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-20673348

RESUMO

BACKGROUND: Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis under physiological and pathological conditions. Anti-VEGF therapy is a clinically proven strategy for the treatment of a variety of cancers including colon, breast, lung, and renal cell carcinoma. Since VEGFR2 is the dominant angiogenic signaling receptor, it has become an important target in the development of novel anti-angiogenic therapies. We have reported previously the development of an antagonistic VEGFR2 peptoid (GU40C4) that has promising anti-angiogenic activity in vitro and in vivo. METHODS: In the current study, we utilize a derivative of GU40C4, termed GU81 in therapy studies. GU81 was tested alone or in combination with doxorubicin for in vivo efficacy in the MMTV-PyMT transgenic model of breast cancer. RESULTS: The derivative GU81 has increased in vitro efficacy compared to GU40C4. Single agent therapy (doxorubicin or GU81 alone) had no effect on tumor weight, histology, tumor fat content, or tumor growth index. However, GU81 is able to significantly to reduce total vascular area as a single agent. GU81 used in combination with doxorubicin significantly reduced tumor weight and growth index compared to all other treatment groups. Furthermore, treatment with combination therapy significantly arrested tumor progression at the premalignant stage, resulting in increased tumor fat content. Interestingly, treatment with GU81 alone increased tumor-VEGF levels and macrophage infiltration, an effect that was abrogated when used in combination with doxorubicin. CONCLUSION: This study demonstrates the VEGFR2 antagonist peptoid, GU81, enhances the anti-tumor activity of doxorubicin in spontaneous murine MMTV-PyMT breast tumors.


Assuntos
Antineoplásicos/farmacologia , Doxorrubicina/farmacologia , Neoplasias Mamárias Experimentais/tratamento farmacológico , Peptídeos/farmacologia , Peptoides/farmacologia , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Animais , Sinergismo Farmacológico , Quimioterapia Combinada , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Técnicas Imunoenzimáticas , Macrófagos/metabolismo , Macrófagos/patologia , Neoplasias Mamárias Experimentais/metabolismo , Neoplasias Mamárias Experimentais/patologia , Vírus do Tumor Mamário do Camundongo/genética , Camundongos , Camundongos Transgênicos , Células Tumorais Cultivadas , Fator A de Crescimento do Endotélio Vascular/farmacologia , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
4.
Neuron ; 62(3): 335-48, 2009 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-19447090

RESUMO

Changes in gene expression contribute to the long-lasting regulation of the brain's reward circuitry seen in drug addiction; however, the specific genes regulated and the transcriptional mechanisms underlying such regulation remain poorly understood. Here, we used chromatin immunoprecipitation coupled with promoter microarray analysis to characterize genome-wide chromatin changes in the mouse nucleus accumbens, a crucial brain reward region, after repeated cocaine administration. Our findings reveal several interesting principles of gene regulation by cocaine and of the role of DeltaFosB and CREB, two prominent cocaine-induced transcription factors, in this brain region. The findings also provide comprehensive insight into the molecular pathways regulated by cocaine-including a new role for sirtuins (Sirt1 and Sirt2)-which are induced in the nucleus accumbens by cocaine and, in turn, dramatically enhance the behavioral effects of the drug.


Assuntos
Cromatina/efeitos dos fármacos , Cocaína/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Núcleo Accumbens/efeitos dos fármacos , Sirtuínas/metabolismo , Animais , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/efeitos dos fármacos , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/metabolismo , Inibidores da Captação de Dopamina/farmacologia , Retroalimentação Fisiológica/efeitos dos fármacos , Estudo de Associação Genômica Ampla , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Núcleo Accumbens/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , Regiões Promotoras Genéticas/efeitos dos fármacos , Regiões Promotoras Genéticas/fisiologia , Proteínas Proto-Oncogênicas c-fos/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-fos/metabolismo , Reforço Psicológico , Transdução de Sinais/efeitos dos fármacos , Sirtuínas/efeitos dos fármacos
5.
Biochemistry ; 44(46): 15247-56, 2005 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-16285728

RESUMO

The VCA domain of the neuronal Wiskott-Aldrich syndrome protein (N-WASP) is a potent activator of the Arp2/3 complex, a 240 kDa heteroheptameric actin-nucleating assembly. We used site-directed spin labeling of N-WASP peptides in conjunction with methyl-TROSY spectra of the intact, selectively labeled Arp2/3 complex to identify regions of the VCA that are proximal to the ARPC3 subunit of the assembly. We also cross-linked CA peptides to the Arp3, Arp2, ARPC1, and ARPC3 subunits. The combined data suggest that the extreme C-terminus of the A region and the C-terminus of the C region of N-WASP are proximal to ARPC3. These results have implications for the mechanism of Arp2/3 complex activation by VCA peptides. This study also demonstrates the utility of NMR spectroscopy for studying ligand binding events in large, asymmetric, macromolecular assemblies.


Assuntos
Complexo 2-3 de Proteínas Relacionadas à Actina/química , Proteína Neuronal da Síndrome de Wiskott-Aldrich/química , Complexo 2-3 de Proteínas Relacionadas à Actina/efeitos da radiação , Proteína 3 Relacionada a Actina/química , Sequência de Aminoácidos , Animais , Bovinos , Reagentes de Ligações Cruzadas/química , Humanos , Dados de Sequência Molecular , Ressonância Magnética Nuclear Biomolecular , Fotoquímica , Proteína Neuronal da Síndrome de Wiskott-Aldrich/efeitos da radiação
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa